Richard K. Wyse

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Slow-SPEED: protocol for three randomised trials of remotely delivered exercise to prevent Parkinson's disease.

Slow-SPEED: protocol for three randomised trials of remotely delivered exercise to prevent Parkinson's disease.

Journal: NPJ Parkinson's disease

Published: February 06, 2026

Protocol of ASPro-PD: a phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson's disease.

Protocol of ASPro-PD: a phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson's disease.

Journal: Journal of neurology

Published: December 11, 2025

Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform.

Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: December 06, 2024

Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update.

Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update.

Journal: Journal of Parkinson's disease

Published: July 20, 2024

Trial of Lixisenatide in Early Parkinson's Disease.

Trial of Lixisenatide in Early Parkinson's Disease.

Journal: The New England journal of medicine

Published: April 10, 2024

Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials Initiative.

Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials Initiative.

Journal: Journal of Parkinson's disease

Published: April 05, 2024

Targeting ferroptosis with the lipoxygenase inhibitor PTC-041 as a therapeutic strategy for the treatment of Parkinson's disease.

Targeting ferroptosis with the lipoxygenase inhibitor PTC-041 as a therapeutic strategy for the treatment of Parkinson's disease.

Journal: PloS one

Published: January 17, 2024

Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson's disease (ROCK-PD).

Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson's disease (ROCK-PD).

Journal: Frontiers in aging neuroscience

Published: October 06, 2023

Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update.

Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update.

Journal: Journal of Parkinson's disease

Published: June 11, 2023

Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update.

Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update.

Journal: Journal of Parkinson's disease

Published: May 09, 2022

Waiting for PARIS-A Biological Target in Search of a Drug.

Waiting for PARIS-A Biological Target in Search of a Drug.

Journal: Journal of Parkinson's disease

Published: November 08, 2021

Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update.

Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update.

Journal: Journal of Parkinson's disease

Published: June 21, 2021

Showing 1-12 of 32

Last Updated: 09/26/2026